Tyme Technologies, Inc. (TYME)
| Market Cap | 306.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.52M |
| Shares Out | 130.17M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 8 |
| Last Price | $1.80 |
| Previous Close | $1.80 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 1.81 |
| Day's Range | 1.73 - 1.88 |
| Day's Volume | 2,322,381 |
| 52-Week Range | 0.85 - 4.99 |
The company closed a $100 million public stock offering.
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that tod...
The clinical-stage biotech provides investors with a quarterly update.
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financia...
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), today announced t...
The U.S. Patent and Trademark Office is on Tyme's side.
Tyme Technologies Inc (NASDAQ: TYME) shares are nearly doubling on above-average volume Wednesday. Tyme, which focuses on developing cancer metabolism-based therapies, said the U.S. Patent and...
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that it ...
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that an ...
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced that, e...
In this article we are going to use hedge fund sentiment as a tool and determine whether Tyme Technologies, Inc. (NASDAQ:TYME) is a good investment right now. We like to analyze hedge fund sen...
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financia...
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its...
TYME Technologies: My Bamboo Speculation In A Potential Leader In Cancer Metabolism-Based Therapies.
TYME Technologies: My Bamboo Speculation In A Potential Leader In Cancer Metabolism-Based Therapies.
Tyme has a solid product candidate in pancreatic cancer.
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.
NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadersh...
NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leaders...
NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leaders...
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.
Tyme Technologies (NASDAQ: TYME) shares are trading higher on Monday after the company announced an orphan drug designation for its SM-88 as a potential treatment for patients with pancreatic ...
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.
NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leaders...
Tyme Technologies Inc (NASDAQ:TYME) was trading 1.7% lower from the previous closing price.
NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced preliminary fina...
NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that TYME will h...
Tyme Technologies Inc (NASDAQ:TYME) was trading 0.2% lower from the previous closing price.
NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced new preclinical ...
NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced new preclinical ...
Tyme Technologies, Inc. (TYME) CEO Steve Hoffman on Q4 2020 Results - Earnings Call Transcript
Tyme Technologies: Market Volatility Provides Opportunity To Accumulate Ahead Of Catalysts
NEW YORK, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced t...
Tyme Technologies: Why Investors Should Be Bullish On The Eagle Partnership
Tyme (TYME) is evaluating its lead cancer candidate, SM-88, as third-line treatment for metastatic pancreatic cancer in a pivotal study.
Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.
Shares of Tyme Technologies were up 23% in premarket trading on Tuesday after the biotechnology company said it had formed a collaboration with Eagle Pharmaceuticals Inc.
Falling knives are companies whose share prices have declined more than 59% over the last 52 weeks.
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that ma...
Tyme Technologies, Inc. (TYME) CEO Steve Hoffman on Q2 2020 Results - Earnings Call Transcript
NEW YORK, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced that i...
Tyme Technologies has several pending events that could inject some positive momentum into the stock. One of these is the final Phase II data for the TYME-88-PANC study at ESMO.
NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that m...
As of late, it has definitely been a great time to be an investor Tyme Technologies.
NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that m...
Tyme Technologies utilizes its Cancer Metabolism-Based Therapies ((CMBTs)) to treat cancers with a huge unmet medical need.
About TYME
Tyme Technologies, a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments f... [Read more...]
| Industry Biotechnology | Founded 2011 |
| Stock Exchange NASDAQ | Ticker Symbol TYME |
Analyst Forecasts
According to 2 analysts, the average rating for TYME stock is "Buy." The 12-month stock price forecast is 8.75, which is an increase of 386.11% from the latest price.